Association of serum gamma-glutamyl transferase with treatment outcome in chronic hepatitis B patients

Figure 1 Baseline serum gamma-glutamyl transferase levels are increased in hepatitis B e antigen-negative and hepatitis B e antigen-positive hepatitis B patients. Data are shown as a median value (10^th-90^th percentile). EPH: Hepatitis B e antigen-positive hepatitis; ENH: Hepatitis B e antigen-negative hepatitis; GGT: Gamma-glutamyl transferase; HC: Healthy control; IC: Inactive carrier; IT: Immune tolerance; ULN: Upper limit of normal.

Figure 2 Serum levels of hepatitis B virus DNA, alanine aminotransferase, and gamma-glutamyl transferase decrease in complete response and non-complete response groups after 48 wk of treatment. A: HBV DNA; B: ALT; C: GGT. Data are shown as the mean ± SE. ALT: Alanine aminotransferase; CR: Complete response; GGT: Gamma-glutamyl transferase; HBV: Hepatitis B virus; NCR: Non-complete response; ULN: Upper limit of normal.

Figure 3 Decline of serum alanine aminotransferase and gamma-glutamyl transferase from baseline differs between complete response and non-complete response groups after 48 wk of treatment. Decline of serum levels for A: HBV DNA; B: ALT; C: GGT plotted as a function of time. Data are shown as the mean ± SE. ALT: Alanine aminotransferase; CR: Complete response; GGT: Gamma-glutamyl transferase; HBV: Hepatitis B virus; NCR: Non-complete response; ULN: Upper limit of normal.

Figure 4 Receiver operating characteristic curves reveal baseline gamma-glutamyl transferase levels as a predictive marker for complete response in hepatitis B e antigen-positive patients following 48 wk of nucleos(t)ide analogue treatment. Specificity and sensitivity values are plotted as a function of ALT, GGT, and HBV DNA levels. AUC is calculated with a 95%CI. ALT: Alanine aminotransferase; AUC: Area under the curve; CI: Confidence interval; GGT: Gamma-glutamyl transferase; HBV: Hepatitis B virus; ULN: Upper limit of normal.